However, the design of complement-based therapies requires comprehensive understanding of the specific mechanisms that involve complement activation in each individual disease, and given the dual role of C3 in AMD, a combination of C3aR inhibitors with blockage of C3b or C3 activation should be considered18. The gene discussed is C3AR1; the disease is age-related macular degeneration.